Next Article in Journal
Flame-Retarded Rigid Polyurethane Foam Composites with the Incorporation of Steel Slag/Dimelamine Pyrophosphate System: A New Strategy for Utilizing Metallurgical Solid Waste
Next Article in Special Issue
Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core
Previous Article in Journal
Donor–Acceptor Complexes of (5,10,15,20-Tetra(4-methylphenyl)porphyrinato)cobalt(II) with Fullerenes C60: Self-Assembly, Spectral, Electrochemical and Photophysical Properties
Previous Article in Special Issue
Cholinesterases Inhibition, Anticancer and Antioxidant Activity of Novel Benzoxazole and Naphthoxazole Analogs
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights

by
Utid Suriya
1,
Panupong Mahalapbutr
2,*,
Watchara Wimonsong
3,
Sirilata Yotphan
3,
Kiattawee Choowongkomon
4,* and
Thanyada Rungrotmongkol
5,6,*
1
Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand
2
Department of Biochemistry, Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khan Kaen 40002, Thailand
3
Department of Chemistry, Center of Excellence for Innovation in Chemistry, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand
4
Department of Biochemistry, Kasetsart University, Bangkok 10900, Thailand
5
Department of Biochemistry, Center of Excellence in Structural and Computational Biology, Chulalongkorn University, Bangkok 10330, Thailand
6
Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand
*
Authors to whom correspondence should be addressed.
Molecules 2022, 27(24), 8901; https://doi.org/10.3390/molecules27248901
Submission received: 6 November 2022 / Revised: 1 December 2022 / Accepted: 7 December 2022 / Published: 14 December 2022
(This article belongs to the Special Issue Enzyme Inhibitors: Design, Synthesis and Biological Evaluation)

Abstract

Combating acquired drug resistance of EGFR tyrosine kinase (TK) is a great challenge and an urgent necessity in the management of non-small cell lung cancers. The advanced EGFR (L858R/T790M/C797S) triple mutation has been recently reported, and there have been no specific drugs approved for this strain. Therefore, our research aimed to search for effective agents that could impede the function of EGFR (L858R/T790M/C797S) TK by the integration of in silico and in vitro approaches. Our in-house quinoxalinone-containing compounds were screened through molecular docking and their biological activity was then verified by enzyme- and cell-based assay. We found that the four quinoxalinone-containing compounds including CPD4, CPD15, CPD16, and CPD21 were promising to be novel EGFR (L858R/T790M/C797S) TK inhibitors. The IC50 values measured by the enzyme-based assay were 3.04 ± 1.24 nM; 6.50 ± 3.02 nM,10.50 ± 1.10 nM; and 3.81 ± 1.80 nM, respectively, which are at a similar level to a reference drug; osimertinib (8.93 ± 3.01 nM). Besides that, they displayed cytotoxic effects on a lung cancer cell line (H1975) with IC50 values in the range of 3.47 to 79.43 μM. In this proposed study, we found that all screened compounds could interact with M793 at the hinge regions and two mutated residues including M790 and S797; which may be the main reason supporting the inhibitory activity in vitro. The structural dynamics revealed that the screened compounds have sufficient non-native contacts with surrounding amino acids and could be well-buried in the binding site’s cleft. In addition, all predicted physicochemical parameters were favorable to be drug-like based on Lipinski’s rule of five, and no extreme violation of toxicity features was found. Altogether, this study proposes a novel EGFR (L858R/T790M/C797S) TK inhibitor scaffold and provides a detailed understanding of compounds’ recognition and susceptibility at the molecular level.
Keywords: EGFR tyrosine kinase; EGFR (L858R/T790M/C797S) TK; lung cancer; non-small cell lung cancer; in silico drug discovery and development EGFR tyrosine kinase; EGFR (L858R/T790M/C797S) TK; lung cancer; non-small cell lung cancer; in silico drug discovery and development

Share and Cite

MDPI and ACS Style

Suriya, U.; Mahalapbutr, P.; Wimonsong, W.; Yotphan, S.; Choowongkomon, K.; Rungrotmongkol, T. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. Molecules 2022, 27, 8901. https://doi.org/10.3390/molecules27248901

AMA Style

Suriya U, Mahalapbutr P, Wimonsong W, Yotphan S, Choowongkomon K, Rungrotmongkol T. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. Molecules. 2022; 27(24):8901. https://doi.org/10.3390/molecules27248901

Chicago/Turabian Style

Suriya, Utid, Panupong Mahalapbutr, Watchara Wimonsong, Sirilata Yotphan, Kiattawee Choowongkomon, and Thanyada Rungrotmongkol. 2022. "Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights" Molecules 27, no. 24: 8901. https://doi.org/10.3390/molecules27248901

APA Style

Suriya, U., Mahalapbutr, P., Wimonsong, W., Yotphan, S., Choowongkomon, K., & Rungrotmongkol, T. (2022). Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. Molecules, 27(24), 8901. https://doi.org/10.3390/molecules27248901

Article Metrics

Back to TopTop